Earnings call transcript: Y-mAbs Therapeutics beats EPS forecast in Q1 2025
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong ex-U.S. revenue growth and reduced net loss are positive, but U.S. revenue decline and increased expenses are concerning. The Q&A highlighted seasonality and competitive pressures as challenges. Guidance for Q2 shows a downtrend, but international growth and potential in new markets offer optimism. Overall, the financial outlook is balanced, with no strong catalysts for significant stock movement within the next two weeks.
Key Financial Performance
Danielza net product revenues $20,900,000 (8% increase from $19,400,000 in Q1 2024) - driven by increased ex U.S. net product revenues.
Ex U.S. Danielza net product revenues $7,500,000 (816% increase from $800,000 in Q1 2024) - driven by the named patient program in Western Asia and product growth in Eastern Asia and Latin America.
U.S. Danielza net product revenues $13,400,000 (28% decrease from $18,600,000 in Q1 2024) - due to slow new patient enrollment, competitive pressures, and changes in ordering patterns from large customers.
Research and development expenses $11,400,000 (decrease of $1,900,000 from $13,300,000 in Q1 2024) - primarily due to a decrease in clinical trial costs and personnel expenses.
Selling, general, and administrative expenses $13,100,000 (increase of $1,700,000 from $11,400,000 in Q1 2024) - driven by increases in personnel costs, business realignment charges, and legal expenses.
Net loss $5,200,000 (decrease from $6,600,000 in Q1 2024) - primarily due to increased net product revenues and favorable foreign currency impacts.
Cash and cash equivalents $60,300,000 (decrease from $67,200,000 at year-end 2024) - representing an investment of $6,900,000 in Q1 2025.
Segment profit from operations (Danielza) $8,800,000 (42% margin) compared to $8,700,000 (44% margin) in Q1 2024.
Segment loss from operations (Radiopharmaceuticals) $6,100,000 compared to $6,000,000 in Q1 2024.
Operating Highlights
Danielza Net Product Revenues Q1 2025: Recorded net product revenues of $20,900,000, an 8% increase from the previous year.
Naxitamab Investigator Sponsored Trial: Kicking off a new investigator sponsored trial led by key members of the Children’s Oncology Group.
NCCN Guidelines Inclusion: Danielza has been added to the NCCN guidelines for treating relapsed or refractory neuroblastoma.
Ex US Danielza Net Product Revenues: Achieved $7,500,000, an increase of $6,700,000 compared to the prior year, driven by named patient programs in Western Asia.
US Danielza Net Product Revenues: Total net product revenues were $13,400,000, down 28% from the prior year due to competitive pressures.
Cash Position: Ended Q1 2025 with $60,300,000 in cash, with an anticipated runway into 2027.
Research and Development Expenses: Decreased to $11,400,000 from $13,300,000 in Q1 2024.
Business Unit Realignment: Established two distinct business units: Danielza and Radiopharmaceuticals to maximize potential and accelerate development.
Radiopharmaceutical R&D Event: Scheduled for May 28 to provide updates on GD2 SADA trial and pipeline.
Risk or Challenges
Competitive Pressures: The company is facing competitive pressures in the U.S. market, particularly with new patient enrollment slowing due to high enrollment in clinical studies and the continued use of available maintenance therapy. This has contributed to a 28% decrease in U.S. net product revenues for Danielza compared to the prior year.
Regulatory Issues: The company is closely monitoring potential regulatory changes and their impact on operations, particularly concerning tariffs that may affect the supply chain. However, they anticipate minimal impact from potential tariff increases.
Supply Chain Challenges: The company has conducted an analysis of its supply chain to understand potential exposure to tariffs, indicating a proactive approach to managing supply chain risks.
Economic Factors: The company has acknowledged a challenging environment with multiple headwinds affecting its operations, including economic factors that may influence patient enrollment and treatment dynamics.
Clinical Trial Risks: The company is advancing its clinical trials but faces challenges in recruiting patients for certain studies, particularly in the relapsed refractory non-Hodgkin's lymphoma indication, which may impact timelines and outcomes.
Financial Guidance: The company has reiterated its financial guidance for 2025, indicating a cautious approach to forecasting amidst the various risks and uncertainties discussed.
Guidance & Outlook
Business Realignment: The company established two distinct internal business units, Danielza and Radiopharmaceuticals, to maximize the potential of Danielza and accelerate the development of the SADACrit platform.
Clinical Trials: The company completed part A of the GD2 SADA phase one clinical trial and dosed the first patient in the CD38 SADA phase one clinical trial.
NCCN Guidelines Inclusion: Danielza has been added to the NCCN guidelines for the treatment of relapsed or refractory neuroblastoma, which is expected to enhance its market position.
Investigator Sponsored Trials: The company is initiating new investigator sponsored trials for Danielza, which will involve key institutions and is expected to expand its market reach.
Q2 2025 Revenue Guidance: Total revenue is expected to be between $17,000,000 and $19,000,000, reflecting seasonal trends and previous stocking orders.
Full Year 2025 Revenue Guidance: The company reiterates its anticipated full year 2025 total revenue guidance of $75,000,000 to $90,000,000.
Cash Runway: The company has a strong financial position with $60,300,000 in cash, providing a runway into 2027.
Operating Expenses: The company is operating below its anticipated cash investment guidance for the full year of 2025.
Shareholder Return Plan
Cash Position: The company ended the first quarter of twenty twenty five with cash and cash equivalents of $60,300,000, which is expected to fund operations into 2027.
Revenue Guidance: The company reiterated its anticipated full year 2025 total revenue guidance, projecting between $75,000,000 and $90,000,000.
Q2 Revenue Guidance: For the second quarter of twenty twenty five, total revenue is expected to be between $17,000,000 and $19,000,000.
Key Q&A
Earnings Word Cloud
YMAB Transcript
The earnings call reveals mixed signals: strong ex-U.S. revenue growth and reduced net loss are positive, but U.S. revenue decline and increased expenses are concerning. The Q&A highlighted seasonality and competitive pressures as challenges. Guidance for Q2 shows a downtrend, but international growth and potential in new markets offer optimism. Overall, the financial outlook is balanced, with no strong catalysts for significant stock movement within the next two weeks.
The earnings call reveals mixed signals: a strong increase in Ex-U.S. revenues but a decline in U.S. revenues. The company faces financial challenges with a net loss and no shareholder return initiatives. Management's optimistic guidance and strategic realignment offer potential upside, but the lack of clarity on regulatory interactions and competitive pressures in the U.S. market counterbalance this. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
The earnings call reveals a mixed performance with declining U.S. revenues, increased expenses, and a net loss, despite some international growth. The lack of a share repurchase program and cash runway concerns add to the negative sentiment. The Q&A section highlights challenges in patient enrollment and vague responses on expenses and market dynamics. While there is a patent extension and a new licensing agreement, these positives are overshadowed by weak guidance and financial challenges, leading to an overall negative sentiment.
The company's financial performance is concerning with a net loss of $29.7 million and declining cash reserves. The lack of a shareholder return plan and unfavorable price mix in the U.S. market further add to the negative sentiment. Despite some international revenue growth, the overall guidance is weak with no clear positive catalysts. The Q&A session highlighted uncertainties and management's vague responses, especially regarding expenses and market dynamics. These factors, coupled with increased operating expenses and lack of strong guidance, suggest a likely negative stock price movement.
YMAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
